Effect of a new drug releasing system on microencapsulated islet transplantation
- PMID: 26722425
- PMCID: PMC4680370
Effect of a new drug releasing system on microencapsulated islet transplantation
Abstract
Objective: This study aimed to develop a novel release system for grafted islets.
Materials and methods: A graphene oxide-FTY720 release system was constructed to test the drug loading and releasing capacity. The recipient rats were divided into four groups as following: Experiment group A (EG A) and B (EG B); Control group A (CG A) and B (CG B). In each group, (2000 ± 100) IEQ microencapsulated islets were implanted into the abdominal cavity of the recipients with oral FTY720, local graphene oxide-FTY720 injection, without immunosuppressants, and with graphene oxide-saturated solution respectively. We detected the immunological data, the blood glucose level, and pericapsular overgrowth to show the transplantation effect.
Results: 31% of adsorptive FTY720 was released within 6 h, and 82% of FTY720 was released within 48 h. From day 5 to 8, the amount of PBL in EG B was significantly less than those in EG A (P<0.01). The CD3+ and CD8+ T lymphocytes were suppressed 3 days longer in EG B than in EG A. On day 19 posttransplantation, the blood glucose level in EG B was much lower than that in EG A (P<0.01). On the same day, pericapsular overgrowth was grade I in EG B, grade II in other groups.
Conclusions: Graphene oxide-FTY720 complex showed a drug releasing effect. Local application of graphene-FTY720 releasing system could decrease the amount of peripheral blood lymphocytes (PBL) and the percentage of CD3 and CD8 T lymphocytes in blood for longer time than oral drug application. This releasing system could achieve a better blood glucose control.
Keywords: Islet transplantation; graphene oxide; immunosuppressants; microencapsulation; overgrowth.
Figures





Similar articles
-
A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons.Transpl Immunol. 1999 Sep;7(3):149-57. doi: 10.1016/s0966-3274(99)80034-3. Transpl Immunol. 1999. PMID: 10608298
-
Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts.Cell Transplant. 1998 Jul-Aug;7(4):403-6. doi: 10.1177/096368979800700409. Cell Transplant. 1998. PMID: 9710310
-
Long-term effect of FTY720 on lymphocyte count and islet allograft survival in mice.Microsurgery. 2007;27(4):300-4. doi: 10.1002/micr.20360. Microsurgery. 2007. PMID: 17477424
-
An engineered macroencapsulation membrane releasing FTY720 to precondition pancreatic islet transplantation.J Biomed Mater Res B Appl Biomater. 2018 Feb;106(2):555-568. doi: 10.1002/jbm.b.33862. Epub 2017 Feb 27. J Biomed Mater Res B Appl Biomater. 2018. PMID: 28240814 Free PMC article.
-
Encapsulated piscine (tilapia) islets for diabetes therapy: studies in diabetic NOD and NOD-SCID mice.Xenotransplantation. 2014 Mar-Apr;21(2):127-39. doi: 10.1111/xen.12086. Epub 2014 Mar 17. Xenotransplantation. 2014. PMID: 24635017
Cited by
-
Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy.Int J Nanomedicine. 2018 Mar 5;13:1265-1280. doi: 10.2147/IJN.S156328. eCollection 2018. Int J Nanomedicine. 2018. PMID: 29551896 Free PMC article.
-
Early-life fingolimod treatment improves intestinal homeostasis and pancreatic immune tolerance in non-obese diabetic mice.Acta Pharmacol Sin. 2021 Oct;42(10):1620-1629. doi: 10.1038/s41401-020-00590-4. Epub 2021 Jan 20. Acta Pharmacol Sin. 2021. PMID: 33473182 Free PMC article.
References
-
- Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science. 1980;210:908–910. - PubMed
-
- Alejandro R, Barton FB, Hering BJ, Wease S Collaborative Islet Transplant Registry Investigators. 2008 Update from the Collaborative Islet Transplant Registry. Transplantation. 2008;86:1783–8. - PubMed
-
- Kobayashi T, Arefanian H, Harb G, Tredget EB, Rajotte RV, Korbutt GS, Rayat GR. Prolonged survival of microencapsulated neonatal porcine islet xenografts in immune-competent mice without antirejection therapy. Cell Transplant. 2008;17:1243–1256. - PubMed
-
- Figliuzzi M, Plati T, Cornolti R, Adobati F, Fagiani A, Rossi L, Remuzzi G, Remuzzi A. Biocompatibility and function of microencapsulated pancreatic islets. Acta Biomater. 2006;2:221–227. - PubMed
-
- Orive G, Tam SK, Pedraz JL, Halle JP. Biocompatibility of alginate-poly-L-lysine microcapsules for cell therapy. Biomaterials. 2006;27:3691–3700. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials